Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.41 USD | -1.35% | +0.45% | +62.62% |
May. 13 | Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab | MT |
May. 13 | Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation | DJ |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.62% | 2.64B | |
+8.92% | 114B | |
+11.39% | 104B | |
-12.23% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-2.53% | 17.89B | |
+8.14% | 14.28B | |
+35.24% | 12.55B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- Transcript : Merus B.V. Presents at Jefferies 2017 Global Healthcare Conference, Jun-08-2017 03